Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
Gastric Cancer Stage IIIB-IIIC
DRUG: Pembrolizumab + SOX
Disease-free survival, the time from the start of surgery to the incurable resection, local recurrence or metastasis, or death from any cause., 3 years
Overall survival, the time from the start of surgery to death due to any cause., 3 years|perioperative complications, perioperative complications, the time from the start of enrollment to 3 months after surgery|Adverse Events, occurs after a clinical trial subject receives a drug, but is not necessarily causally related to the treatment., the time from the start of enrollment to 90 days after using drugs/ 30 days after surgery
it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer